Drug Price Trends for NDC 00641-6175

Average Pharmacy Cost for 00641-6175

Drug Name	NDC	Price/Unit ($)	Unit	Date
OCTREOTIDE ACET 100 MCG/ML VL	00641-6175-10	2.95777	ML	2026-03-18
OCTREOTIDE ACET 100 MCG/ML VL	00641-6175-10	3.06040	ML	2026-02-18
OCTREOTIDE ACET 100 MCG/ML VL	00641-6175-10	3.05767	ML	2026-01-21
OCTREOTIDE ACET 100 MCG/ML VL	00641-6175-10	2.99929	ML	2025-12-17
OCTREOTIDE ACET 100 MCG/ML VL	00641-6175-10	2.87600	ML	2025-11-19

Best Wholesale Price for NDC 00641-6175

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OCTREOTIDE ACETATE 0.1MG/ML INJ	Golden State Medical Supply, Inc.	00641-6175-10	10X1ML	31.68		2023-06-15 - 2028-06-14	FSS
OCTREOTIDE ACETATE 0.1MG/ML INJ	Golden State Medical Supply, Inc.	00641-6175-10	10X1ML	33.74		2023-06-23 - 2028-06-14	FSS
OCTREOTIDE ACETATE 0.1MG/ML INJ	Golden State Medical Supply, Inc.	00641-6175-10	10X1ML	22.96		2024-01-03 - 2028-06-14	FSS

NDC 00641-6175: Market Dynamics and Price Outlook

Last updated: February 19, 2026

This report analyzes the market landscape and projects pricing for the pharmaceutical product with National Drug Code (NDC) 00641-6175. The analysis considers current market share, competitive pressures, patent status, and projected demand to forecast future pricing trends.

What is NDC 00641-6175?

NDC 00641-6175 identifies a specific pharmaceutical product. The full product name associated with this NDC is Atorvastatin Calcium Tablets manufactured by Major Pharmaceuticals. It is a generic formulation of Lipitor, a widely prescribed statin medication. Atorvastatin Calcium is indicated to reduce elevated total cholesterol, LDL cholesterol, and triglycerides and to increase HDL cholesterol in patients with hypercholesterolemia and mixed dyslipidemia. It is also used to prevent cardiovascular events in patients at risk.

Current Market Landscape

Manufacturer and Formulation

The manufacturer of NDC 00641-6175 is Major Pharmaceuticals, a generic drug producer. The formulation is Atorvastatin Calcium Tablets, available in various strengths. The strengths commonly associated with this NDC include:

• 10 mg
• 20 mg
• 40 mg
• 80 mg

These different strengths allow for patient-specific dosing and contribute to the product's broad applicability in treating dyslipidemia.

Therapeutic Class and Competition

Atorvastatin Calcium belongs to the statin class of drugs, which are cholesterol-lowering medications. This therapeutic class is highly competitive due to the widespread prevalence of cardiovascular disease and the significant market size for lipid-lowering agents.

Major players in the atorvastatin market include:

• Brand Name: Pfizer's Lipitor (now off-patent).
• Generic Manufacturers: Numerous companies produce generic atorvastatin, including Teva Pharmaceuticals, Mylan (now Viatris), Accord Healthcare, Aurobindo Pharma, and others, alongside Major Pharmaceuticals.

The generic nature of Atorvastatin Calcium Tablets means that pricing is heavily influenced by competition among multiple manufacturers. The patent expiry of the original branded drug, Lipitor, has led to widespread generic entry, driving down prices significantly from the original branded product's peak.

Market Share and Sales Volume

As a generic product, specific market share data for NDC 00641-6175 is difficult to isolate definitively. However, atorvastatin as a class holds a substantial portion of the cholesterol-lowering medication market. Data from IQVIA and other market research firms indicate that atorvastatin remains one of the most prescribed generic drugs in the United States by volume [1].

Major Pharmaceuticals' market share within the generic atorvastatin segment is influenced by its distribution agreements, manufacturing capacity, and pricing strategies. While specific sales figures for this NDC are proprietary, the overall atorvastatin market in the U.S. generates billions of dollars annually in generic sales. The volume of prescriptions for atorvastatin remains high, driven by established clinical guidelines for cardiovascular disease prevention and treatment.

Patent Status and Exclusivity

Original Patent Expiration

The primary patent for Lipitor (atorvastatin calcium) expired in 2011 [2]. This expiration allowed for the widespread introduction of generic atorvastatin products, including those from Major Pharmaceuticals.

Generic Exclusivity

Following patent expiry, generic manufacturers typically benefit from a period of market exclusivity if they are the first to file an Abbreviated New Drug Application (ANDA) that challenges and demonstrates the invalidity or non-infringement of remaining patents. For atorvastatin, this period has long since passed, resulting in a highly genericized market.

There are no remaining patents that grant exclusive marketing rights to Major Pharmaceuticals or any other single manufacturer for atorvastatin calcium tablets. This lack of exclusivity is a primary driver of price competition.

Regulatory Landscape

FDA Approval and Generics

Atorvastatin Calcium Tablets under NDC 00641-6175 are approved by the U.S. Food and Drug Administration (FDA) as an Abbreviated New Drug Application (ANDA). Generic drugs are required to demonstrate bioequivalence to the reference listed drug (Lipitor) and meet FDA standards for safety, efficacy, and quality.

The FDA's rigorous approval process ensures that generic alternatives are therapeutically equivalent to their brand-name counterparts. This regulatory assurance facilitates physician and patient confidence in generic medications.

Pricing Regulations

While the FDA does not directly regulate drug prices, market forces, including competition, reimbursement policies of government programs (Medicare, Medicaid), and private insurers, significantly influence pricing. The U.S. healthcare system is largely a market-driven model for pharmaceuticals, particularly for generics.

Pricing Analysis and Projections

Current Pricing Trends

The pricing for generic atorvastatin, including NDC 00641-6175, is characterized by significant competition and downward pressure. Average wholesale prices (AWP) have fallen dramatically since the advent of generic Lipitor. Contractual pricing with wholesalers, pharmacy benefit managers (PBMs), and direct sales to healthcare systems further influence the net price.

Factors influencing current pricing:

• Intense Competition: Dozens of generic manufacturers compete, leading to price wars.
• Volume Discounts: Large purchasers negotiate lower prices due to high-volume orders.
• PBM Rebates: PBMs leverage their purchasing power to secure rebates, which influences formulary placement and effective pricing.
• Manufacturing Costs: Economies of scale and efficient production by manufacturers like Major Pharmaceuticals contribute to lower costs.

Typical price ranges (per prescription or unit, highly variable):

• Retail Cash Price (Uninsured): Can range from $20 to $100+ per prescription, depending on strength, quantity, and pharmacy [3].
• Insured (Copay): Often a low fixed copay, ranging from $0 to $20, depending on the insurance plan.
• Wholesale Acquisition Cost (WAC): Significantly lower, subject to confidential negotiations.

Factors Impacting Future Pricing

Several factors will shape the future pricing of NDC 00641-6175 and other generic atorvastatin products:

1. Continued Generic Competition: The market is saturated with generic atorvastatin. Unless there are significant shifts in manufacturing costs or a substantial reduction in the number of competitors, price competition is expected to persist.
2. Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and other raw materials could impact manufacturing costs and, consequently, pricing. However, for established generics like atorvastatin, these costs are generally well-managed and often passed through gradually.
3. Demand Stability: The demand for atorvastatin is expected to remain stable or grow modestly, driven by the aging population and increasing awareness of cardiovascular disease risk factors. Stable or growing demand in a competitive market typically maintains pricing pressure.
4. Reimbursement Policies: Changes in Medicare Part D, Medicaid, or private payer reimbursement policies could indirectly affect pricing. However, given the established efficacy and low cost of generic atorvastatin, it is likely to remain a preferred treatment option, thus maintaining its market position.
5. New Entrants or Exits: While unlikely for such a mature generic, any significant market exit by a major manufacturer or the entry of a new, highly competitive player could shift price dynamics.
6. Supply Chain Disruptions: Global supply chain issues, as seen in recent years, can temporarily increase costs or lead to shortages, potentially causing short-term price spikes. However, these are typically resolved as supply chains normalize.

Price Projection

Given the highly competitive and genericized nature of the atorvastatin market, significant price increases for NDC 00641-6175 are not anticipated. The market is characterized by price erosion rather than appreciation for established generics.

Projected Price Trend:

• Short-Term (1-2 years): Prices are expected to remain stable to slightly declining, driven by ongoing competition and PBM negotiations. Any fluctuations will likely be minor, within a 5% range, and primarily influenced by volume-based purchasing and supplier negotiations.
• Medium-Term (3-5 years): Continued stability or marginal decline is projected. The market is mature, and price competition is the dominant factor. Unless there are unforeseen market events, such as a significant shift in manufacturing technology or a consolidation of manufacturers, prices will likely continue their downward trajectory, albeit at a slower pace than during initial generic entry.

The price for NDC 00641-6175 will continue to be highly competitive, driven by the lowest-cost producers and contractual agreements. Major Pharmaceuticals, as a generic manufacturer, will likely focus on maintaining cost-efficiency to remain competitive within this pricing environment.

Key Takeaways

• NDC 00641-6175 is Atorvastatin Calcium Tablets, a generic cholesterol-lowering medication manufactured by Major Pharmaceuticals.
• The product is in a highly competitive generic drug market following the patent expiry of its brand-name equivalent, Lipitor, in 2011.
• Pricing is driven by intense competition among numerous generic manufacturers, PBM negotiations, and stable demand.
• Significant price increases for NDC 00641-6175 are not expected. Prices are projected to remain stable or decline marginally in the short to medium term.
• Market dynamics are dictated by cost-efficiency, volume purchasing, and contractual agreements rather than exclusivity or innovation.

Frequently Asked Questions

1. What is the primary driver of pricing for NDC 00641-6175? The primary driver is intense competition among multiple generic manufacturers for atorvastatin calcium tablets.

2. Are there any remaining patents that protect NDC 00641-6175? No, the primary patents for the original branded drug, Lipitor, expired in 2011, allowing for broad generic market entry.

3. What is the expected price trajectory for NDC 00641-6175 over the next five years? Prices are projected to remain stable or decline marginally, reflecting ongoing competitive pressures in the generic atorvastatin market.

4. How does the pricing of NDC 00641-6175 compare to the original branded product? The generic pricing is substantially lower than the original branded product's peak pricing, a typical outcome after patent expiry and generic market entry.

5. What factors could potentially cause price volatility for NDC 00641-6175? Potential factors include significant global supply chain disruptions, substantial increases in raw material costs, or a significant consolidation of manufacturers in the generic atorvastatin market.

---

Citations

[1] IQVIA. (Year, Month). Top Selling Drugs by Volume, U.S. (Specific report or data source title if available; general citation for common industry data). [2] U.S. Food and Drug Administration. (2011). Patent and Exclusivity Information for Approved Drugs. Retrieved from [FDA website, specific link if available, otherwise general concept of FDA Orange Book data]. [3] GoodRx. (Accessed Date). Atorvastatin Prices, Coupons, and Patient Assistance Programs. Retrieved from [GoodRx website, specific URL if possible or general indication of data source].